FAMILY STUDIES OF MEPHENYTOIN HYDROXYLATION DEFICIENCY
- 1 May 1986
- journal article
- research article
- Vol. 38 (5), 768-772
Abstract
A genetic polymorphism characterized by deficient drug oxidation exists for the hydroxylation of mephenytoin. This deficiency was first recognized in a family study that suggested an autosomal recessive pattern of inheritance. To confirm the observation, we investigated 28 relatives of five poor metabolizers. Subjects ingested 50 mg of mephenytoin, and the 24-hr urine was analyzed for hydroxymephenytoin. The pedigree data shown here provide strong evidence that deficient mephenytoin hydroxylation is an autosomal recessive trait.This publication has 11 references indexed in Scilit:
- Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians.British Journal of Clinical Pharmacology, 1985
- INVITRO INHIBITION STUDIES OF 2 ISOZYMES OF HUMAN-LIVER CYTOCHROME-P-450 - MEPHENYTOIN PARA-HYDROXYLASE AND SPARTEINE MONOOXYGENASE1985
- Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphismClinical Pharmacology & Therapeutics, 1984
- Mephenytoin and sparteine pharmacogenetics in Canadian CaucasiansClinical Pharmacology & Therapeutics, 1984
- Mephenytoin hydroxylation deficiency: Kinetics after repeated dosesClinical Pharmacology & Therapeutics, 1984
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- STEREOSELECTIVE METABOLISM AND DISPOSITION OF THE ENANTIOMERS OF MEPHENYTOIN DURING CHRONIC ORAL-ADMINISTRATION OF THE RACEMIC DRUG IN MAN1982
- Stereoselective metabolism of mephenytoin in man.1981
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979